RESUMEN
Malaria is a serious but preventable and treatable infectious disease that is found in over 100 countries around the world. Correct and rapid diagnosis of malaria infection can rescue the patient of getting sicker and reduces the risk of disease spreading among humans. Chlamydomonas reinhardtii chloroplast is an attractive platform for expressing malaria antigens because it is capable of folding complex proteins, including those requiring disulfide bond formation, while lack the ability to glycosylate proteins; a valuable quality of any malaria protein expression system, since the Plasmodium parasite lacks N-linked glycosylation machinery. In this study, Cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen from Plasmodium falciparum was expressed in the chloroplast of C. reinhardtii and a highly sensitive and specific indirect ELISA test was developed using C. reinhardtii expressed PfCelTOS to detect malaria. Results obtained demonstrated that expressed recombinant PfCelTOS accumulates as a soluble, properly folded and functional protein within C. reinhardtii chloroplast and indirect ELISA using sera from malaria-positive donors suggested the potential use of expressed PfCelTOS as a malaria antigen for diagnosis tests.
Asunto(s)
Antígenos de Protozoos/genética , Chlamydomonas reinhardtii , Cloroplastos/metabolismo , Malaria/diagnóstico , Plasmodium falciparum/inmunología , Proteínas Protozoarias/genética , Antígenos de Protozoos/metabolismo , Biotecnología , Cloroplastos/genética , Ensayo de Inmunoadsorción Enzimática , Expresión Génica , Humanos , Malaria/sangre , Plantas Modificadas Genéticamente , Plasmodium falciparum/genética , Proteínas Protozoarias/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Sensibilidad y Especificidad , Pruebas SerológicasRESUMEN
Malaria is an infectious disease having a large negative impact on economic growth. Vaccines are considered as a novel strategy to reduce the burden of malaria. Malaria parasite has a complex life cycle and attempts are being made to develop vaccines that target each stage of the life cycle. Oral vaccines seem to be more feasible to implement in poor countries, since they are relatively inexpensive, needle-free administrated, mostly stable at non-refrigerated conditions and painless. By using recombinant technology, suitable oral hosts could serve as antigen delivering vehicles in developing oral vaccines. Chlamydomonas reinhardtii offers beneficial attributes as oral recombinant protein expression platform. Moreover, C. reinhardtii chloroplast is an attractive platform for expressing malaria antigens because it is capable of folding complex proteins, including those requiring disulfide bond formation, while lacking the ability to glycosylate proteins; a valuable quality of any malaria protein expression system, since the Plasmodium parasite lacks N-linked glycosylation machinery. As a first step towards developing an oral vaccine candidate against malaria, here, we expressed a fusion protein consisting of PfCelTOS, a candidate for pre-erythrocytic and transmission-blocking vaccines, fused to human interleukin-2 (IL-2) as vaccine adjuvant in the chloroplast of C. reinhardtii. The effect of light and media on recombinant protein production and cell growth was then studied. Results demonstrated that expressed recombinant proteins accumulate as a soluble, properly folded and functional protein within algal chloroplasts. Moreover, results showed that the highest cell density can be achieved using mixotrophy mode. However, protein accumulation appears to be favored by cultivating in TAP medium in low light.
Asunto(s)
Antígenos de Protozoos , Chlamydomonas reinhardtii , Cloroplastos , Vacunas contra la Malaria , Plasmodium falciparum/genética , Antígenos de Protozoos/biosíntesis , Antígenos de Protozoos/genética , Chlamydomonas reinhardtii/genética , Chlamydomonas reinhardtii/metabolismo , Cloroplastos/genética , Cloroplastos/metabolismo , Vacunas contra la Malaria/biosíntesis , Vacunas contra la Malaria/genéticaRESUMEN
BACKGROUND: Recombinant protein technology has revolutionized the world of biology and medicine. Following this progress, fusion protein technology, as a novel innovation, has opened new horizons for the development of proteins that do not naturally exist. Fusion proteins are generated via genetically fusing two or more genes coding for separate proteins, thus the product is a single protein having functional properties of both proteins. As an indispensable element in fusion protein construction, linkers are used to separate the functional domains in order to improve their expression, folding and stability. METHOD: We computationally fused an antigen and an adjuvant together using different linkers to obtain a two-domain fusion construct which can potentially act as an oral vaccine candidate against malaria. We then predicted the structures computationally to find out the probable folding of each domain in the designed construct. RESULTS: One of the fusion constructs was selected based on the highest value for C-score. Ramchandran Plot analysis represented that most residues were fallen in favorable regions. CONCLUSION: Our in silico analysis showed that (GGGGS)3 linker confers the best structure and stability for our target fusion protein.
Asunto(s)
Vacunas contra la Malaria/química , Proteínas Protozoarias/química , Proteínas Recombinantes de Fusión/química , Vacunas Sintéticas/química , Vacunas contra la Malaria/genética , Vacunas contra la Malaria/metabolismo , Modelos Moleculares , Conformación Proteica , Pliegue de Proteína , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Vacunas Sintéticas/genética , Vacunas Sintéticas/metabolismoRESUMEN
BACKGROUND: Malaria infection is still widespread in some parts of the world and threatens the lives of millions of people every year. Vaccines, especially oral vaccines are considered to be effective in reducing the burden of malaria morbidity and mortality. By using recombinant technology, suitable oral hosts could serve as antigen delivering vehicles in developing oral vaccines. This study was aimed towards designing and computational analysis of a fusion protein consisting of Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS) fused to human interleukin-2 (IL-2) and M cell-specific peptide ligand (Co1), as a step toward developing a vaccine candidate. RESULTS: To our best knowledge, the three dimensional (3D) structure of CelTOS is not reported in protein database. Therefore, we carried out computational modeling and simulation in the hope of understanding the properties and structure of PfCelTOS. Then we fused IL-2 to PfCelTOS by a flexible linker and did in silico analysis to confirm the proper folding of each domain in the designed fusion protein. In the last step, Co1 ligand was added to the confirmed fusion structure using a rigid linker and computational analysis was performed to evaluate the final fusion construct. One structure out of five predicted by I-TASSER for PfCelTOS and fusion constructs was selected based on the highest value for C-score. Molecular dynamics (MD) simulation analysis indicated that predicted structures are stable during the simulation. Ramchandran Plot analysis of PfCelTOS and fusion constructs before and after MD simulation also represented that most residues were fallen in favorable regions. CONCLUSION: In silico study showed that Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS construct has a constant structure and the selected linkers are effectively able to separate the domains. Therefore, data reported in this paper represents the first step toward developing of an oral vaccine candidate against malaria infection.
Asunto(s)
Diseño de Fármacos , Eritrocitos/inmunología , Interleucina-2/química , Vacunas contra la Malaria/química , Simulación de Dinámica Molecular , Plasmodium falciparum/inmunología , Proteínas Protozoarias/inmunología , Adyuvantes Inmunológicos , Antígenos de Protozoos/inmunología , Humanos , Interleucina-2/inmunología , Malaria/inmunología , Malaria/prevención & control , Vacunas contra la Malaria/administración & dosificación , Vacunas contra la Malaria/inmunología , Plasmodium falciparum/citología , Plasmodium falciparum/metabolismo , Conformación Proteica , Proteínas Recombinantes/inmunología , Esporozoítos/inmunologíaRESUMEN
Microalgae, also called microphytes, are a vast group of microscopic photosynthetic organisms living in aquatic ecosystems. Microalgae have attracted the attention of biotechnology industry as a platform for extracting natural products with high commercial value. During last decades, microalgae have been also used as cost-effective and easily scalable platform for the production of recombinant proteins with medical and industrial applications. Most progress in this field has been made with Chlamydomonas reinhardtii as a model organism mainly because of its simple life cycle, well-established genetics and ease of cultivation. However, due to the scarcity of existing infrastructure for commercial production and processing together with relatively low product yields, no recombinant products from C. reinhardtii have gained approval for commercial production and most of them are still in research and development. In this review, we focus on the chloroplast of C. reinhardtii as an algal recombinant expression platform and compare its advantages and disadvantages to other currently used expression systems. We then discuss the strategies for engineering the chloroplast of C. reinhardtii to produce recombinant cells and present a comprehensive overview of works that have used this platform for the expression of high-value products.
Asunto(s)
Chlamydomonas reinhardtii/crecimiento & desarrollo , Cloroplastos/genética , Ingeniería de Proteínas/métodos , Chlamydomonas reinhardtii/genética , Cloroplastos/metabolismo , Genoma del Cloroplasto , Estadios del Ciclo de Vida , Proteínas Recombinantes/biosíntesisRESUMEN
BACKGROUND: Pivotal roles of Nerve growth factor (NGF) in the development and survival of both neuronal and non-neuronal cells indicate its potential for the treatment of neurodegenerative diseases. However, investigation of NGF deficits in different diseases requires the availability of properly folded human ß-NGF. In previous studies bacterial expression of hNGF demonstrated the feasibility of its overproduction. However, known limitations in the use of E. coli as an expression host for a protein with three intra-chain disulfide bonds were evident. OBJECTIVES: Here an optimized system was developed to overexpress the soluble NGF in E. coli. MATERIALS AND METHODS: The gene encoding the ß subunit of mature hNGF was optimized based on E. coli codon preference and cloned into pET-32a expression vector providing His- and Trx- tags for detection and increasing the solubility of recombinant protein, respectively. The recombinant DNA was expressed in E. coli Origami (DE3), which enhances the correct formation of disulfide bonds in the cytoplasm of E. coli. Different culture conditions were evaluated to increase soluble expression of the target protein. RESULTS: The highest soluble expression level was achieved when E. coli Origami (DE3) cells expressing NGF were grown at 30ºC in TB medium with 0.2 mM IPTG induction at OD600nm = 1 for 4 h. CONCLUSIONS: Our results indicated that the recombinant NGF was successfully expressed as a soluble form.